Following these findings, a phase 1b study has demonstrated that the combination of magrolimab, a well-tolerated humanized anti-CD47 antibody, with AZA showed a greater ORR compared to AZA treatment alone, with a more rapid response time in AML patients ([252], NCT03248479). The gene discussed is CD47; the disease is acute myeloid leukemia.